{
    "symbol": "RDY",
    "quarter": 4,
    "year": 2022,
    "date": "2022-05-19 17:03:06",
    "content": " We regained milestone revenue of $1 billion in North America generics, improved market share in most of our major markets, EBITDA and ROCE in the range of our aspirational targets, generation of strong free cash flow leading to a net surplus of more than $200 million, entered high-growth space of medical cannabis business in Germany to acquisition of Nimbus Health, exclusive collaboration with Novartis for in-licensing of key brands in India market and significant progress made in our digitalization and sustainability journey."
}